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Abstract
Fructose 2,6-bisphosphate is present at high concentrations in many established lines of transformed cells. It plays a key
role in the maintenance of a high glycolytic rate by coupling hormonal and growth factor signals with metabolic demand.
The concentration of fructose 2,6-bisphosphate is controlled by the activity of the homodimeric bifunctional enzyme
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2). We report here the PFKFB-3 gene expression control by
insulin in the human colon adenocarcinoma HT29 cell line. The incubation of these cells with 1 WM insulin resulted in an
increase in the PFK-2 mRNA level after 6 h of treatment, this effect being blocked by actinomycin D. Furthermore, insulin
induced ubiquitous PFK-2 protein levels, that were evident after a lag of 3 h and could be inhibited by incubation with
cycloheximide. ; 2002 Elsevier Science B.V. All rights reserved.
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The metabolism of many tumors and neoplastic or
transformed cell lines is characterized by their high
rate of glycolysis even under aerobic conditions [1].
The speci¢c regulatory mechanisms responsible for
enhanced glycolysis and the novo nucleic acid syn-
thesis in transformed cells have remained largely ob-
scure. A stimulation of glycolysis can also be ob-
served following exposure of quiescent cells to
growth and tumorigenic factors [2,3]. The discovery
of fructose 2,6-bisphosphate (Fru-2,6-P2), a potent
activator of 6-phosphofructo-1-kinase (PFK-1) [4^
7], has focused attention on this important control
point of the glycolytic pathway. Indeed, Fru-2,6-P2 is
present at high concentrations in many neoplastic
cells where it plays a key role in the maintenance
of a high glycolytic rate [2,4^7].
The concentration of Fru-2,6-P2 is controlled by
the homodimeric bifunctional enzyme 6-phospho-
fructo-2-kinase/fructose 2,6-bisphosphatase (PFK-2)
that is responsible for both the formation and deg-
radation of this compound [4^7]. Since the discovery
of rat liver PFK-2, several mammalian isozymes have
been identi¢ed in di¡erent tissues. These isozymes
are generated by alternative splicing from only four
genes, designated PFKFB 1^4 [7^10].
Stimulation of glycolysis was observed in chick
embryos [11] and human ¢broblasts [12,13] and in
HT29 colon adenocarcinoma cells [14,15] upon expo-
sure to mitogenic concentrations of insulin. Stimula-
tion of lactate production by insulin was found to
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correlate with Fru-2,6-P2 level and PFK-2 activity
[11,15]. The mechanism of PFK-2 activation by in-
sulin was not known, although a stimulation of tran-
scription and/or translation had been suggested [2].
HT29 cells, derived from a human colon adenocarci-
noma, display a very active glycolytic pathway and
insulin produces an induction of Fru-2,6-P2 concen-
tration, PFK-2 activity and lactate production [15].
We have now examined if these changes induced by
insulin involve the transcriptional regulation of the
ubiquitous PFKFB-3 gene. In fact, PFKFB-3 codes
for a PFK-2 isozyme present in proliferating and
transformed cells that displays a high kinase/bisphos-
phatase activity ratio that may be essential for tumor
cell growth [16^19].
Exponentially growing HT29 cells were maintained
during 24 h in serum-free medium to induce their
quiescence and then stimulated with 1 WM insulin
or phosphate bu¡ered saline (PBS). As shown in
Fig. 1A, a speci¢c band corresponding to the prod-
uct of PFKFB-3 gene (ubiquitous PFK-2 mRNA)
was detected in HT29 cells by Northern blot hybrid-
ization using as a probe a PFKFB-3-speci¢c 3P
cDNA region [17]. The incubation of HT29 cells
with 1 WM insulin resulted in a 2.2 L 0.2-fold increase
in PFK-2 mRNA levels after 6 h of treatment. In-
cubation of HT29 cells with an inhibitor of RNA
transcription (actinomycin D) blocked the insulin de-
pendent PFK-2 mRNA expression, showing that this
e¡ect was at the transcriptional level. Cycloheximide,
an inhibitor of protein synthesis, had a minor inhib-
itory e¡ect on PFK-2 mRNA expression (Fig. 1B),
suggesting the possible participation of some new
translated protein in this insulin e¡ect.
Recently, Chesney et al. cloned an inducible iso-
form of PFK-2 that only di¡ers from the ubiquitous
isoform in a 23-nucleotide insertion in the 3P end of
the coding region of the mRNA [19]. These two
PFK-2 cDNA products are generated through alter-
native splicing of the same gene (PFKFB-3) [20]. The
23-nucleotide di¡erentially spliced exon of the induc-
ible isoform causes a change of the reading frame
giving rise to a protein that di¡ers in the C-terminal
amino acid sequence and it is inducible by lipopoly-
saccharide (LPS) in monocytes [19]. In order to de-
termine if HT29 cells expressed inducible PFK-2, we
attempted a RT-PCR ampli¢cation of total RNA
obtained from these cells. The RT-PCR only ampli-
¢ed a single band of the same length as the positive
control, corresponding to the ubiquitous cDNA (Fig.
1C). Cycle sequencing of the PCR ampli¢ed products
showed that only the ubiquitous isoform was present
in these cells (data not shown).
To evaluate the modulation exerted by insulin on
ubiquitous PFK-2 protein levels, we generated a spe-
ci¢c antibody against ubiquitous PFK-2 by subcuta-
Fig. 1. E¡ect of insulin on PFKFB-3 mRNA expression. (A)
HT29 cells were incubated with insulin (1 WM) for 3 or 6 h. (B)
HT29 cells treated for 6 h with insulin and 35 WM cyclohexi-
mide (CHX) or 2.5 Wg/ml actinomycin D (ActD). Total RNA
was extracted and analyzed by Northern blot with a speci¢c
probe for ubiquitous PFK-2 [17]. (C) RT-PCR ampli¢cation.
Two micrograms of total RNA from HT29 cells were reverse-
transcribed using a Ready-To-Go T-Primed First-Strand Kit
(Amersham Pharmacia Biotech) and oligo(dT) as primer. PCR
ampli¢cation was carried out using 2 Wl of the reverse-tran-
scribed RNA product from HT29 cells (HT29 lane) or uPFK-2
cDNA (C+ lane) and the gene-speci¢c oligonucleotides LR-5
(5P-CACACACCGGGAGAGG-3P, corresponding to position
1434 bp of ubiquitous PFK-2 cDNA) and LR-3 (5P-
TCGTTCCCATGAGGCGTC-3P, corresponding to position
2191 bp), in a GeneAmp PCR System 2400 from Perkin-Elmer.
All panels are representative of three di¡erent experiments.
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neous immunization of white New Zealand rabbits
with an ubiquitous PFK-2 carboxy-terminal peptide
((NH2)-CMKGSRSSADSSRKH-(COOH)) that was
conjugated to keyhole limpet hemocyanin. This pep-
tide comprises a unique region of the ubiquitous
PFK-2 (amino acids 507^520) that di¡ers signi¢-
cantly from the corresponding portion of inducible
PFK-2 [19]. This antibody does not recognize the
liver or testis isoform overexpressed in COS-1 cells
(Fig. 2A) that were identi¢ed by an antibody against
liver PFK-2. As shown in Fig. 2B, HT29 cell incu-
bation in the presence of insulin produced an in-
crease in ubiquitous PFK-2 protein concentration
that was evident after a lag of 3 h (Fig. 2C). This
induction was inhibited by incubation of HT29 cells
with cycloheximide, showing that translation was
necessary (Fig. 2D).
It has been reported that insulin stimulates glucose
uptake and lactate production in HT29 cells [14,15].
The accumulation of Fru-2,6-P2 which is induced by
insulin in these cells is concomitant with the increase
of PFK-2 activity and glycolysis [15], and this e¡ect
closely resembles that observed in other transformed
cell lines [11^13,19,21,22]. The results herein reported
demonstrate that the PFK-2 isozyme present in
HT29 cells is the ubiquitous PFK-2 isoform coded
by the PFKFB-3 gene. Moreover, they also show
that insulin controls PFK-2 in these cells mainly by
the transcriptional regulation of PFKFB-3 gene,
since addition of actinomycin D completely blocked
its induction. These results also explain those previ-
ously presented that demonstrated that PFK-2 from
HT29 cells was di¡erent from the liver isozyme and
shared some common characteristics with the heart
isoform [15].
Insulin is a major regulator of cell glucose metab-
olism and controls the expression of speci¢c genes.
Despite the importance of insulin in gene regulation,
little is known about the cis-elements and trans-act-
ing factors which mediate insulin action [23]. Re-
cently, it has been shown that the transcription fac-
tor sterol regulatory binding protein-1c (SREBP-1c)
is transcriptionally stimulated by insulin in the liver
and can mediate insulin action on the expression of
glucokinase and lipogenesis-related genes through
binding to sterol regulatory elements (SRE, 5P-
TCACCCCCAC-3P) and E-boxes (5P-CANNTG-3P)
[24^26]. Several SRE sequences and E-boxes, identi-
¢ed in the promoter region of the PFKFB 3 gene
[20], could be responsible for this action. Direct in-
volvement of these elements on the regulation by
insulin must be further evaluated.
In conclusion, the results now reported show that
ubiquitous PFK-2 isozyme is present in HT29 cells
and that its gene is transcriptionally regulated by
insulin, playing a key role in the maintenance of
high glycolytic rates in this cell line derived from a
human colon adenocarcinoma.
Fig. 2. E¡ect of insulin on PFK-2 protein levels. (A) Western
blot of COS cell extracts overexpressing PFK-2 cDNA of ubiq-
uitous, liver or testis isozyme, using an anti-ubiquitous PFK-2-
speci¢c antibody (left) or anti-liver PFK-2 one [27] (right). (B)
HT29 cells were treated with 1 WM of insulin at di¡erent times.
(C) The densitometric data of B are represented. Each point
represents the meanLS.E.M. of the data obtained by densito-
metric scanning from three independent experiments using
monoclonal antibody anti-L-tubulin (from Oncogene) for nor-
malization. (D) HT29 cells were treated for 6 h with insulin in
the presence or absence of 35 WM cycloheximide. Protein lysates
were analyzed by Western blot.
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